BVZ-AMFA

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameBVZ-AMFA
Drug Alias NameN/A
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor A degradersInsulin-like growth factor II receptor modulators
TargetsVascular endothelial growth factor AInsulin-like growth factor II receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanoMedSyn
China Registration ClassN/A

Develop Information

Active CompaniesNanoMedSyn
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A